Please assess the completion status of the following clinical trial:

Trial Title: Obalon Balloon System Pivotal IDE (SMART) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female between the ages of 22-64 years~2. Current BMI of 30.0 - 40 kg/m2~3. Previously attempted to lose weight unsuccessfully using a medically supervised or non-medically supervised diet~4. Willing to attend all protocol-specified follow-up visits plus any additional follow-up visits as required throughout the entire study period~5. Willing to avoid non-commercial air travel and scuba diving during the entire study period~6. Willing to avoid medications or other substances known to effect weight changes during the study~7. Willing to avoid Non-Steroidal Anti-inflammatory Drugs (NSAIDs) or other medications known to be gastric irritants during the study~8. Willing to use contraception and avoid pregnancy during the study if the subject is female with child bearing potential~9. Willing to provide written informed consent~Exclusion Criteria:~1. Significant weight loss in the past 12 months~2. Use of medications or other substances known to induce weight gain or weight loss~3. Participation in any clinical study at the start of this trial or in the last year~4. Known history of endocrine disorders affecting weight~5. Currently receiving chronic steroid or immunosuppressive therapy or has previously been diagnosed with HIV~6. Subjects diagnosed with bulimia, binge eating, compulsive overeating, high liquid calorie intake habits or similar eating related psychological disorders~7. Intent to undergo gastric surgery or gastric banding during the study period or within the 6 month period after completion of this study~8. Prior use of any weight loss medical device~9. Known history of structural or functional disorders of the esophagus~10. Known history of structural or functional disorder of the esophagus, including any swallowing disorder, esophageal chest pain disorders, or drug refractory esophageal reflux symptoms~11. Known history of structural or functional disorders of the stomach~12. Known history of a structural or functional disorder of the stomach, including any symptoms of chronic upper abdominal pain, chronic nausea, chronic vomiting, chronic dyspepsia or symptoms suggestive of gastroparesis, including post-prandial fullness or pain, post-prandial nausea or vomiting or early satiety~13. Known history of duodenal ulcer, intestinal diverticula (diverticulitis), intestinal varices, intestinal stricture/stenosis, small bowel obstruction, or any other obstructive disorder of the gastrointestinal (GI) tract~14. Currently have ongoing symptoms suggestive of intermittent small bowel obstruction, such as recurrent bouts of post-prandial abdominal pain, nausea or vomiting~15. Known history irritable bowel syndrome, radiation enteritis or other inflammatory bowel disease, such as Crohn's disease~16. Known history of GI surgeries that may have resulted in anatomical GI tract abnormalities~17. Type 1 diabetes~18. Type 2 diabetes requiring insulin or other hypoglycemic oral agents.~19. Experienced a myocardial infarction, has a known history of angina, a known history of congestive heart failure, or is currently being medically treated for any other cardiac condition~20. Poorly controlled hypertension, (≥ 160 mmHg Systolic and ≥ 100mmHg Diastolic).~21. End stage renal disease or requiring hemodialysis within the past 6 months~22. Unwilling or unable to avoid Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including Aspirin, Diclofenac, Ibuprofen, Naproxen, or other medications known to be gastric irritants beginning two weeks prior to enrollment and throughout the entire study period~23. Subjects taking medications on specified hourly intervals that may be affected by changes to gastric emptying~24. Subjects requiring the use of anti-platelet drugs or other agents affecting the normal clotting of blood~25. Untreated or unstable alcohol or illicit drug addiction~26. Known history of allergies to any component of the device materials~27. Currently pregnant or breastfeeding or intention of becoming pregnant during the study~28. Life expectancy less than 1 year or severe renal, hepatic, pulmonary or other medical condition, in the opinion of the investigator~29. Subject is employed by the investigator, or is a close relative of the investigator, or the investigator's staff~30. Subject is a close relative of another subject already enrolled in the study.~31. Any other condition that, in the opinion of the investigator, would interfere with subject participation, may confound the study results, or interfere with compliance with the study (e.g., psychosocial issues).

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group (Type: ACTIVE_COMPARATOR): In accordance with the randomization assignment, treatment arm subjects will receive a 6-month course of Balloon therapy with a nutrition and lifestyle program. Balloon treatment consists of placement of 3 balloons Obalon Intragastric Balloons in the first 3 months of therapy.
- Control Group (Type: SHAM_COMPARATOR): Control arm subjects will receive a single 6-month course of sham device therapy with a nutrition and lifestyle program. Sham treatment consists of placement of 3 shams in the first 3 months of therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete